Chairs: Raymond Chung and Barbara Rehermann

• 1:00 p.m. - 1:20 p.m. Translational immunology in oncology: a successful paradigm for cure studies? - David Brooks
• 1:20 p.m. - 1:30 p.m. Efficacy of therapeutic vaccination with a novel checkpoint modifier - Sue Currie
• 1:30 p.m. - 1:40 p.m. Leveraging prior vaccination to enhance functional cure rates in siRNA/IFN-α combination studies - David Margolis
• 1:40 p.m. - 1:50 p.m. ImmTAV®: Soluble, bi-specific T cell receptors to target HBsAg-positive hepatocytes - Lucy Dorrell
• 1:50 p.m. - 2:00 p.m. Anti-HBs combination therapies for treatment in HBV/HDV patients - Michael Chattergoon
• 2:00 p.m. - 2:40 p.m. Discussion